
Critical Care Guidelines FOR CRITICAL CARE USE ONLY

Phosphate Replacement Guideline





PHOSPHATE

Critical Care Guidelines FOR CRITICAL CARE USE ONLY

Critical Care Guidelines



FOR CRITICAL CARE USE ONLY

PHOSPHATE

PRESENTATION:	Addiphos 20ml vials containing 40mmol phosphate, 30mmol sodium and 30mmol potassium.	
	Phosphate 500ml polyfusor containing 50mmol phosphate, 9.5mmol potassium and 81mmol sodium.	
	Potassium acid phosphate 10ml ampoules containing 10mmol phosphate (1mmol/ml) and 10mmol potassium.	
	Sodium glycerophosphate 20ml ampoules containing 20mmol phosphate (1mmol/ml) and 40mmol sodium.	
INDICATION:	Hypophosphataemia.	
	See previous page.	
DOSE AND ADMINISTRATION:	Addiphos:	
	 Central IV administration: 20ml Addiphos made up to 60ml with glucose 5% over 6 hours. 	
	 Peripheral IV administration 20ml Addiphos made up to 500ml with glucose 5% over 6 hours. 	
	Phosphate polyfusor:	
	 Central or peripheral IV administration: 500ml polyfusor administered over 12 hours (Can be given centrally over 6 hours if required). 	
	If hypernatraemia a concern: Potassium Acid Phosphate - Central IV administration: 40ml made up to 60ml with glucose 5% over 6 hours.	
	If hyperkalaemia a concern: Sodium Glycerophosphate: - Central IV administration: 40ml made up to 60ml with glucose 5% over 6 hours.	
	 Peripheral IV administration: 40ml made up to 500ml with glucose 5% over 8 hours. 	
STABILITY:	Physically and chemically stable for 24 hours at room temperature.	

References:

- 1) UKCPA Minimum Infusion Volumes, Fourth Edition, December 2012. Accessed December 2020. https://www.scottishintensivecare.org.uk/uploads/2014-07-24-19-56-30-Minimuminfusionvolumesinl-40262.pdf
- 2) Injectable Medicines Guide, Medusa, accessed December 2020. https://medusa.wales.nhs.uk/Home.asp
- 3) Sodium Glycerophosphate, Summary of product characteristics, Fresenius Kabi. Updated March 2017. Accessed December 2020. https://www.fresenius-kabi.com/nz/documents/Glycophos Datasheet.pdf
- 4) Sterile Potassium Acid Phosphate, Martindale Pharmaceuticals, SPC, updated January 2015. Accessed December 2020. https://www.medicines.org.uk/emc/product/3572/smpc#gref
- 5) Anecdotal experience in Critical Care units in NHS Lothian since 2010.
- 6) Personal communication with Fresenius-Kabi Medicines Information regarding stability of products 02/2014.
- 7) Personal communication with Fresenius –Kabi Medicines Information regarding stability of products 09/2015.

Title: Phosphate		
ID: Version 3	Authors: E Tang, C Hannah, G Smyth, A Neally, M Cromarty, H Veitch.	
Status Draft/Final: FINAL	Approved by: Lothian Critical Care QIT Editorial Group.	
	Written: January 2022	
Updated on: January 2022	Next review : Janauary 2024	